Liu 2020.

Study characteristics
Methods	Study design: retrospective cohort Type of publication: preprint Setting and dates: ICU (intervention); hospital ward (comparator), 8 February 2020‐3 April 2020 Country: China Language: English Number of centres: 1 Trial registration number: NR
Participants	Number of participants: 154 allocated (intervention = 61; comparator = 93) Age: 72.41 ± 10.4 years (mean ± SD) in intervention group, 70.1 ± 11.01 years (mean ± SD) in comparator group Gender: 94 (61%) male Comorbidities: NR Confounding factors: prior anticoagulation (NR), surgery (NR), cancer (NR), antiplatelet use (NR), history of VTE (NR) Type of ventilator support: NR Inclusion criteria COVID‐19 confirmed by a PCR test Exclusion criteria NR
Interventions	Intervention of interest: with anticoagulation (heparin). Type and dose were not described Comparator: without anticoagulation Concomitant therapy: possible use of tocilizumab, but the proportion of participants was not described Duration of follow‐up: NR
Outcomes	There is no differentiation between primary and secondary outcomes. Mortality Laboratorial parameters (blood routine characteristics, coagulation parameters) Thrombocytopenia
Notes	Sponsor/funding: grants 2016CB02400 and 2017YFC1201103 from the National Major Research and Development Program of China. The study authors declare that "The founder of this study did not contributed to data collection, analysis, and interpretation, and the manuscript preparation." COIs: all study authors declare no competing interests